Weiss Ratings Reiterates Sell (E+) Rating for Apyx Medical (NASDAQ:APYX)

Key Points

• Weiss Ratings has restated its "Sell (E+)" rating for Apyx Medical (NASDAQ: APYX), indicating ongoing concerns about the company's performance.
• Apyx Medical reported a quarterly loss of ($0.09) earnings per share, matching expectations, while revenue of $11.37 million fell short of analyst projections.
• Institutional investors hold approximately 55.33% of Apyx Medical's stock, with several large firms recently adjusting their positions in the company.

Apyx Medical (NASDAQ:APYX - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Apyx Medical Stock Performance

APYX traded up $0.31 during trading hours on Friday, hitting $3.21. The stock had a trading volume of 127,050 shares, compared to its average volume of 110,886. The company's fifty day simple moving average is $2.34 and its 200 day simple moving average is $1.91. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $3.49. The stock has a market cap of $121.40 million, a PE ratio of -7.13 and a beta of 1.46. The company has a quick ratio of 3.95, a current ratio of 4.72 and a debt-to-equity ratio of 4.61.

Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Apyx Medical had a negative return on equity of 158.22% and a negative net margin of 37.11%.The company had revenue of $11.37 million during the quarter, compared to analyst estimates of $11.69 million. Apyx Medical has set its FY 2025 guidance at EPS. Equities analysts anticipate that Apyx Medical will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in APYX. Fisher Asset Management LLC bought a new stake in shares of Apyx Medical during the 2nd quarter valued at about $34,000. Kingsview Wealth Management LLC lifted its position in Apyx Medical by 9.4% in the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company's stock worth $431,000 after buying an additional 16,502 shares during the last quarter. Joel Isaacson & Co. LLC purchased a new position in Apyx Medical in the 1st quarter worth approximately $28,000. Osaic Holdings Inc. purchased a new position in Apyx Medical in the 2nd quarter worth approximately $50,000. Finally, Salem Investment Counselors Inc. purchased a new position in Apyx Medical in the 3rd quarter worth approximately $97,000. Institutional investors own 55.33% of the company's stock.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.